Compare Herbalife Nutrition Ltd (HLF) vs Novavax Inc (NVAX) Price & Performance

HLF trades at $12.25, up 2.17% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.64, beating expectations, and raised full-year guidance. Revenue remains stable around $5 billion annually, with a net income margin of 4.66%. Valuation ratios appear attractive with a P/E of 5.26 and P/S of 0.25. Debt-to-asset ratio improved to 71.67% in 2025, reflecting progress in deleveraging.

The outlook is mixed: strong analyst support (57.69% buy ratings) and operational improvements contrast with high debt levels and negative shareholder equity. Key risks include competitive pressures and reliance on international growth. Near-term catalyst is Q2 2026 earnings on August 5, 2026.

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.